New hope: Pharmaceutical company Regeneron has announced the results of a trial of a new crown monoclonal drug.

In addition to vaccines, human methods to combat the new coronavirus pandemic include designing new drugs specifically designed to fight the disease,media reported. It is believed that we have seen a lot of reports about monoclonal antibody drugs, these drugs can release cloned antibodies that can mediat the virus. This antibody can be based on human or animal antibodies and designed for human use. Some of these drugs actually contain more than one antibody to achieve potential mutations that stimulate SARS-CoV-2.

The meso-antibodies injected into the patient’s body work much like plasma, but they may be more effective than plasma. For plasma, it is certainly hoped that donors will produce a large number of powerful antibodies and bind to the virus to help victims recover more quickly. But monoclonal drugs already use the strongest antibodies with higher concentrations.

In addition, monoclonal therapy provides vaccine-like protection for patients who are not infected with the new coronavirus. As long as these antibodies circulate in the blood, they can identify and heal the virus. This means that taking one of these drugs actually makes people temporarily immune to the new coronavirus.

Regeneron is one of the pharmaceutical companies testing new crown monoclonal drugs using REN-COV2, a mixture of two antibodies that involves multiple clinical trials. Regeneron on Tuesday released the results of a trial targeting new crown patients treated at home rather than in hospitals.

New hope: Pharmaceutical company Regeneron has announced the results of a trial of a new crown monoclonal drug.

The pharmaceutical company recruited 275 patients for randomized trials, which divided them into three equal groups: the placebo group, the high-dose group (8g REGN-COV2) and the low-dose group (2.4g REGN-COV2). The scientists then tested patients for new coronary antibodies to see if the immune system had begun to remove the virus that infected the body. They found that 45 percent of patients were found to have antibodies (serum-positive), 41 percent did not have any antibodies (serum-negative), and 14 percent were unsure.

For now, Regeneron hasn’t released the full results of the special trial, and it’s unclear which antibodies are being tested.

About 56 percent of the patients tested were Hispanic, 13 percent were African-American, and 64 percent had one or more potential risk factors. More than 40% of them are obese. The average age of the subjects was 44 years, of which 49 per cent were men and 51 per cent were women. Regeneron found that REGN-COV2 helped serum-negative patients the most, suggesting that monoclonal antibody therapy may be effective in patients who are unable to produce a rapid immune response on their own.

In the placebo group, sero-positive people needed 7 days to clear symptoms, while serum-negative people needed 13 days. Serum-negative patients stopped reporting symptoms after 28 days of taking 8g REGN-COV, while patients taking 2.4g of the drug needed only 6 days to eliminate symptoms.

Regardless of the dose used, REGN-COV2 can help serum-negative patients significantly reduce viral load on the 7th day. The scientists found that after seven days of REN-COV2 treatment, the higher the initial level of the virus, the greater the decrease.

When it comes to side effects, the company says there were serious side effects in two placebo-using patients, one in the low-dose group and one in the high-dose group, but did not specify. However, there were no deaths in the trial.

It is reported that the 2/3 trial will involve 1300 patients for 29 days, in the second phase of the trial will be conducted every 2-3 days PCR trial.

In addition to the trials mentioned above, Regeneron has conducted reGEN-COV2 studies on hospitalized patients (Phase 2/3) and trials to prevent new crown infections in family contacts are in Phase 3.